middle.news
Acrux Advances Female Testosterone Therapy with Phase III Trial and $21 Billion Market Potential
9:02am on Thursday 6th of August, 2026 AEST
•
Healthcare
Read Story
Acrux Advances Female Testosterone Therapy with Phase III Trial and $21 Billion Market Potential
9:02am on Thursday 6th of August, 2026 AEST
Key Points
Phase II results show significant improvement in sexual health
Phase III trials planned in US and Australia with FDA and TGA feedback
US HSDD market potential estimated at US$21.3 billion annually
Proprietary patchless MDTS delivery system offers patient-friendly application
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE